Zhang [26] reported a significant elevation of plasma APE1/Ref-1 in patients with non-small-cell lung carcinoma, compared with controls (median: 0.159 vs. 0.091 ng/mL, respectively; p < 0.001). Here, APEX1 is linked to non-small cell lung carcinoma.